Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
17 November 2009 - 2:30PM
PR Newswire (US)
DURHAM, N.C., Nov. 17 /PRNewswire-FirstCall/ -- Oxygen
Biotherapeutics, Inc. (OTC:OXBT) (BULLETIN BOARD: OXBT) today
announced that the company has begun shipping Dermacyte(TM) Oxygen
Concentrate Gel to customers who have pre-ordered through the
BuyDermacyte.com website. The shipments, which are going out today,
cover orders received through early November. "This is a major
milestone event for our company - actually shipping a product to
customers and generating revenue as a result," said Chris Stern,
company chairman and CEO. "Orders are continuing to come in and we
will be shipping on a regular basis. We believe that our new
cosmetic line has the potential to be a significant financial
contributor and intend to move forward with our aggressive market
and product plans and pursue our goal to cover our running costs
with product sales." The gel is a first product of a broad and
diverse Dermacyte product line in development. It uses a
combination of patented and secret formulations to make the skin
appear moist and more youthful. Dermacyte Oxygen Concentrate Gel
can be purchased directly from the company via the secure ordering
website at http://www.buydermacyte.com/. About Oxygen
Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is dedicated to
commercializing innovative pharmaceuticals and medical devices in
the field of oxygen therapeutics and Defense Medicine(TM). The
company has developed a perfluorocarbon (PFC) therapeutic oxygen
carrier and liquid ventilation product (Oxycyte(TM)) and has
out-licensed an implantable glucose sensor. These products are
based upon core technologies that include biomedical applications
for PFCs as well as medical and industrial applications for
biosensors. Each of the product candidates is designed with
advantages over currently marketed products in major markets
including traumatic brain injury, sickle cell crisis, trauma, wound
care, decompression sickness, acute respiratory distress syndrome,
stroke, myocardial infarction, surgery, diabetes wounds and ulcers,
and cosmetic applications which are being marketed under the
Dermacyte name. More information is available at
http://www.oxybiomed.com/. Caution Regarding Forward-Looking
Statements This news release contains certain forward-looking
statements by Oxygen Biotherapeutics, Inc. referring to
expectations and plans for Dermacyte Oxygen Concentrate Gel that
involve risks and uncertainties and reflect the company's judgment
as of the date of this release. There can be no assurance that
Dermacyte orders will grow or even continue or that Dermacyte sales
will cover running costs or contribute any meaningful revenue to
the company. Additional information concerning these and other risk
factors affecting Oxygen Biotherapeutics, Inc.'s business can be
found in the company's public periodic filings with the Securities
and Exchange Commission, which are available via
http://www.oxybiomed.com/. Oxygen Biotherapeutics, Inc. disclaims
any intent or obligation to update these forward-looking statements
beyond the date of this release. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. DATASOURCE: Oxygen Biotherapeutics, Inc. CONTACT: Abe
Wischnia of Abe Wischnia & Associates, +1-619-795-2345, for
Oxygen Biotherapeutics, Inc. Web Site: http://www.oxybiomed.com/
http://www.buydermacyte.com/
Copyright